Beyond The Guidance: The Business Of Co-Development Combinations
This article was originally published in Pharmaceutical Approvals Monthly
FDA put together its well-received draft guidance on co-development of experimental drugs to be used in combination in less than a year, but even with regulators on board and the science burgeoning, the timeline for finding predictable ways for companies to actually collaborate on combining investigative cancer therapies looks to be much longer.
You may also be interested in...
Bill proposes six months’ extra marketing exclusivity to spur development of combinations of investigational drugs for serious diseases. Setting aside prospects for passage in an election season, the question is whether that will be enough to get pharma to buy into a risky development space and pioneer a new business model.
The drug makers, potential competitors, will study Bristol's CTLA-4 inhibitor Yervoy in combination with Roche's investigational BRAF inhibitor vemurafenib in metastatic melanoma.